Biocitech SAS Residents Continue to Boost Innovation in Response to Challenging Economic Times

Published: Apr 10, 2012

Biocitech, April 10, 2012 – Biocitech, the Paris life sciences technology park, announces today that the 27 enterprises based onsite continued to invest, innovate and sign contracts in 2011. Many indicators show positive growth, including the number of scientists, who now represent 317 out of 551 personnel working on the site.

Innovation indicators in 2011 include nine proofs of concept, up 30 per cent; 177 patents applied for, up 17 per cent; and five preclinical milestones achieved, up 60 per cent. Residents consider they have collectively made 60 significant scientific advances, up seven per cent compared with 2010.

This productivity in scientific and technological activity illustrates the continuing progress in R&D, as residents lay firm foundations for their ultimate goals of bringing products and services developed at Biocitech to market. Apart from R&D advances, the quality of the work carried out by Biocitech residents is illustrated by 14 international scientific publications, an increase of seven per cent on 2010, and their attendance at 117 scientific meetings, nearly half as many again as in the previous year.

Biocitech itself organized 15 national and international scientific events, bringing together more than 1,200 participants. At a local level, a colloquium in conjunction with local authorities, a local university, and small, medium and large companies in the area demonstrated how life sciences are contributing to the present and future of the Seine-Saint Denis department close to Paris.

Progress further downstream was more limited against a background of economic difficulties experienced generally in the life science field. Phase I trial starts numbered seven and Phase II just one. Residents reported one example of in-licensing and two of out-licensing.

On the other hand, contracts continued to be signed - 13, up 40 per cent, in 2011, collaboration agreements between Biocitech residents came in at 22, up 1. This campus effect makes it easy for residents to work together and develop joint offers. There was however a drop in partnerships with outside companies, down eight per cent to 52, in particular with international companies, which more than halved to 11, another indicator of the depressed economic climate in 2011.

The enterprises based at Biocitech are all innovative start-ups. Some of the more recently created have shown extraordinary growth rates but overall the residents’ revenues declined by 15 per cent. Funding from grants and similar sources also dropped to EUR 6.5 million, and a similar trend saw equity funding drop to EUR 2.85 million against EUR 30 million in 2010. The total equity raised by Biocitech residents since its creation in 2003 remains an impressive EUR 404.1 million.

Most Biocitech residents share a pessimistic view of 2012 which they believe will be no better than 2011 in terms of raising funds either through winning contracts or equity.

Despite the generally downbeat view of 2011, four new companies set up their base at Biocitech during the 12 months. They operate in different areas, all offering services that add to the variety of skills available at Biocitech. They are: Biobank for Life, a biological sample storage specialist; Helios Biosciences, bioinformatics; Mitologics, screening; and PupPharma, preclinical pediatric research.

“2011 was not an easy year for the economy and this has been especially true for innovative start-ups like those we host at Biocitech,” said Jean-François Boussard, president of Biocitech. “Our residents have however continued to make discoveries and scientific progress and to recruit highly qualified personnel despite economic difficulties. I believe that Biocitech’s shared facilities and the potential for collaboration deals between companies based here has cushioned our residents from the worst of these tough economic times.”

About Biocitech

Biocitech is a technology park dedicated to life sciences and the environment. It offers resident companies on-site support from inception to maturity. It provides a range of services that are specifically designed for firms in the sectors of biotechnology, biopharmaceuticals, fine chemicals, medical and in vitro diagnostics, and medical devices.

Biocitech is the only science and technology park in the Paris area that is ICPE certified, and that offers a comprehensive and flexible range of services that include technical buildings, multi-technical services and support services. ICPE certification provides entrepreneurs with secure premises of a high technological standard that are perfectly adapted to their development. The unique combination gives firms the benefit of specialized resources that cost less because they are pooled. Biocitech is located close to Raymond Queneau Paris subway station, and is only 20 minutes from Charles de Gaulle airport.

The park is market-oriented and the great majority of its residents generate revenues from the sale of products or services. Furthermore, the firms installed at Biocitech complement one another, thus generating strong synergies and numerous collaborations.

Along with other organizations in the Paris area, Biocitech is a key element in the Medicen Paris Region network, the Greater Paris region’s world-class competitiveness hub for health and new therapies.

For further information, go to:

Mark Tidmarsh


Follow us on Twitter:

Brighton Business Centre 95 Ditchling Road Brighton BN1 4ST ENGLAND

Tel: +44 1273 675100

Fax: +44 1273 675400

55 rue Boissonade 75014 Paris FRANCE

Tel: +33 1 56 54 07 00

Fax: +33 1 56 54 07 01


Back to news